Caisson Biotech has announced former Novozymes president Glenn Nedwin as the company's CEO and president.
He will lead the US biotech as it looks to make the most of a multi-million dollar technology access and license agreement with Novo Nordisk agreed in May, 2012.
“Glenn's comprehensive background in operations, business and product development, and market focus will take Caisson to the next level,” said Thomas Harlan, president of Emergent Technologies – the parent company of Caisson.
Nedwin spent 14 years as president of Danish biotech Novozymes from 1992 to 2006, co-founding the company's US R&D headquarters.
He later joined Danisco as executive VP of its Genencor division, where he was responsible for the technical enzyme business unit.
During this period, he was a member of the team that discovered TNF-alpha and -beta, among other human cytokines.
Most recently, Nedwin was president of the human therapeutics division of Intrexon.
“I am very excited to join Caisson Biotech as CEO and president,” said Nedwin. “Caisson's novel, natural HEPtune drug delivery technology for improved drug performance perfectly fits the needs of the pharmaceutical industry.
“We are seeking additional corporate partners for our technology and we intend to become a leader in drug delivery.”
In addition to his role at Caisson, Nedwin is also a board member of Emergent Technologies and co-editor in chief of the journal Industrial Biotechnology.